Who was tested. How it was applied. And what effects did it have on those people, some of the questions that are answered in this note.
The vaccine against him coronavirus from Modern showed promising results and could be ready by 2021. This morning, the laboratory announced that its effectiveness reaches 94.5%. The Argentine government, for now, has not confirmed conversations to acquire it, but the first reports indicate that in the United States it could cost between 30 and 40 dollars. Currently, the study is in phase 3.
It is an investigational vaccine against the SARS-CoV-2 virus was well tolerated Y generated an antibody activity neutralizers in healthy adults in which it was tested in the United States, according to provisional studies released by The News England Journal of Medicine and cited by official US sources.
The vaccine is called MRNA-1273, is developed by researchers from the National Institute of Allergies and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and Modern Pharma, based in Cambridge (Massachusetts), USA. .UU.
In the early phases of the study, the vaccine was tested on 45 people, between 18 and 55 years old.
To these people it was applied two doses of mRNA-1273 administered with 28 days apart at three levels (25, 100, 250 micrograms) in the 45 adult participants, all healthy, and returned results on day 57.
“The phase 1 data demonstrate that vaccination with mRNA-1273 causes a robust immune response at all dose levels, ”said Moderna’s chief medical officer, Tal Zaks, in July.
For his part, Moderna’s executive director, Stéphane Bancel, described the “positive data” from this first phase as “encouraging”. “They represent an important step forward in the clinical development of mRNA-1273, our vaccine candidate against Covid-19,” he added.
Specifically, the two doses of the vaccine caused a greater amount of antibodies than what people who have had Covid disease generate.
The NIH put it this way: the doses “triggered high levels of activity of neutralizing antibodies that were above the average values observed in convalescent sera obtained from people with confirmed disease ”.
Regarding the health safety of the volunteers, “no serious adverse events were reported”, but some participants did suffer some kind of effect.
“More than half of the participants reported fatigue, headache, chills, myalgia, or pain at the place of application “, the statement detailed, which specified that adverse events” were more common after the second vaccination and in those who received the highest dose. “
The trial was extended last April to people over 55 years old. On July 8, Moderna announced that it was preparing phase 3 of its experimental vaccine against Covid-19, which will include 30,000 participants in the US. and that it was “on track to start in July.” This Monday, the result was finally known.
According to Moderna, “the company is on track to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year starting in 2021.”
According to the World Health Organization (WHO), some 300 coronavirus vaccines are currently in the testing phase.
With information from EFE and DPA